Cancer in Finland

IARC estimates 36,289 new cancer cases and 13,674 cancer deaths in Finland in 2024; the commonest new cancers are prostate, breast and colorectum. This page is assembled automatically from OnCo's data: 213 trials with a site there, 8 institutions, 6 companies, 9 people and 1 programme or law, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

36,289

all cancers

Deaths

13,674

all cancers

Incidence rate

258.9

per 100,000, age-standardised

Mortality rate

77.9

per 100,000, age-standardised

Cumulative risk

25.7%

of a cancer by age 74

Population

5,617,316

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	5,564	78.8	Prostate cancer
Breast	5,204	87.3	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Colorectum	4,349	28.7	Colorectal cancer
Trachea, bronchus and lung	2,913	17.6	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Melanoma of skin	2,029	17.1	Melanoma
Non-Hodgkin lymphoma	1,593	11.2	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Pancreas	1,437	8.4	Pancreatic ductal adenocarcinoma
Bladder	1,353	7.6	Bladder & urothelial cancer
Kidney	980	7.6	Renal cell carcinoma
Corpus uteri	910	12.7	Endometrial cancer

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	2,330	13.5	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	1,515	8.2	Colorectal cancer
Pancreas	1,354	7.7	Pancreatic ductal adenocarcinoma
Prostate	958	9.6	Prostate cancer
Breast	914	11.5	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Liver and intrahepatic bile ducts	619	3.6	Hepatocellular carcinoma
Non-Hodgkin lymphoma	591	3.0	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Stomach	418	2.6	Gastric & gastro-oesophageal junction cancer
Brain, central nervous system	403	3.7	Glioma & glioblastoma
Oesophagus	375	2.5	Oesophageal cancer

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Finland”, in Northern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

213 trials in OnCo · 64 recruiting overall

213 trials

Trial			Lead sponsor
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497	Phase 3	Recruiting	Merck Sharp & Dohme LLC	244	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354	Phase 3	Recruiting	Merck Sharp & Dohme LLC	281	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl NCT06824467	Phase 3	Recruiting	Merck Sharp & Dohme LLC	197	2026-10-06
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164	Phase 3	Recruiting	Merck Sharp & Dohme LLC	54	2026-10-06
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374	Phase 3	Recruiting	Merck Sharp & Dohme LLC	314	2026-10-06
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma NCT06697301	Phase 2/3	Recruiting	Eikon Therapeutics	127	2026-10-06
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624	Phase 3	Recruiting	Merck Sharp & Dohme LLC	288	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer NCT07166094	Phase 3	Recruiting	Genmab	177	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re NCT07225270	Phase 3	Recruiting	Genmab	34	2026-10-06
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	77	2026-10-06
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) NCT06796907	Phase 1/2	Recruiting	GlaxoSmithKline	82	2026-10-02
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422	Phase 3	Recruiting	Merck Sharp & Dohme LLC	242	2026-10-02
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re NCT05519085	Phase 3	Recruiting	Celgene	266	2026-09-30
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P NCT07361510	Phase 3	Recruiting	Bristol-Myers Squibb	284	2026-09-30
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment NCT07472517	Phase 3	Recruiting	Boehringer Ingelheim	245	2026-09-29
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy NCT07544654	Phase 3	Recruiting	Boehringer Ingelheim	167	2026-09-29
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) NCT07099898	Phase 3	Recruiting	GlaxoSmithKline	135	2026-09-28
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) NCT07144280	Phase 3	Recruiting	Pfizer	449	2026-09-28
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT06667076	Phase 2	Recruiting	Janssen Research & Development, LLC	204	2026-09-25
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide NCT05623020	Phase 3	Recruiting	Pfizer	160	2026-09-25
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. NCT06629779	Phase 3	Recruiting	Pfizer	233	2026-09-25
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC NCT04892173	Phase 3	Recruiting	Johnson & Johnson Enterprise Innovation Inc.	193	2026-09-25
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL NCT05748171	Phase 2	Recruiting	Pfizer	65	2026-09-24
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. NCT05727904	Phase 3	Recruiting	Iovance Biotherapeutics, Inc.	82	2026-09-24
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En NCT07028853	Phase 3	Recruiting	Pfizer	307	2026-09-24
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal NCT07293351	Phase 1/2	Recruiting	Bristol-Myers Squibb	95	2026-09-23

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Finland, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Finland is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

8 institutions

Cancer Society of Finland Docrates Cancer Center Finnish Cancer Center (FICAN)HUS Comprehensive Cancer Center, Helsinki University Hospital Kuopio University Hospital Cancer Center Oulu University Hospital Tays Cancer Centre, Tampere University Hospital Turku University Hospital Cancer Centre

6 companies

Faron Pharmaceuticals Kaiku Health (Elekta)Modulight MVision AI Orion, Orion Pharma TILT Biotherapeutics

9 people

People whose main affiliation in OnCo is an institution or company in Finland.

Annika Auranen Arto Mannermaa Heikki Joensuu Johanna Mattson Juha Korpelainen Pia Vihinen Satu Tiainen Sirkku Jyrkkiö Tomi P. Mäkelä

Screening, vaccination and law

Term

Cervical cancer screening programme in Finland

Finland runs a national cervical cancer screening programme started in 1963, offering cytology (Pap test), as recorded by IARC's CanScreen5 survey (2016).

Approvals

Finland is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Finland's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Finland, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Finland's own sources, beyond the programme records above.

A deep dive for Finland is ranked 54 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/fi.json; every country: /api/v1/countries.json.